Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2022

Q1 2022 biggest moves
  • HZNPHZNP

    HORIZON THERAPEUTICS PUB L

    New

    1.1% of portfolio

  • GILDGILD

    Gilead Sciences

    New

    1.0% of portfolio

  • PTGXPTGX

    Protagonist Therapeutics

    Sold out

    was 0.8% of portfolio

  • CNCCNC

    Centene

    Cut 45%

    now 1.0% of portfolio

67 changes in all

Top Holdings122 positions

Checking export access…
Activity:
??
GLAUKOS CORPDelisted
Bond
269.9M$358.8M8.0%——
4 qtrssince 2021-Q2
Increased
77
NUVL
NUVLDelisted

NUVALENT INC

19.3M$268.6M6.0%——
3 qtrssince 2021-Q3
Unchanged
0
VTRS

Viatris Inc.

20.7M$224.9M5.0%$14.06-36.22%
6 qtrssince 2020-Q4
Decreased
0
AHCO

AdaptHealth Corp.

11.7M$186.8M4.2%$23.56-31.97%
10 qtrssince 2019-Q4
Increased
64
??
INVITAE CORPDelisted
Bond
206.9M$169.8M3.8%——
7 qtrssince 2020-Q3
Increased
69
NBIX

Neurocrine Biosciences, Inc.

1.7M$155.4M3.5%$94.61-0.90%
5 qtrssince 2021-Q1
Increased
66
157.4M$141.9M3.2%——
7 qtrssince 2020-Q3
Unchanged
0
52.5M$123.9M2.8%——
4 qtrssince 2021-Q2
Unchanged
0
??
CAREMAX INCDelisted
15.9M$121.8M2.7%——
4 qtrssince 2021-Q2
Decreased
0
??
NATERA INCDelisted
Bond
90.6M$120.2M2.7%——
4 qtrssince 2021-Q2
Increased
83
88.7M$116.1M2.6%——
1 qtr
New
78
81.6M$100.9M2.3%——
3 qtrssince 2021-Q3
Unchanged
0
??
NUVASIVE INCDelisted
Bond
97M$96.4M2.2%——
4 qtrssince 2021-Q2
Unchanged
0
LUNG

Pulmonx Corporation

3.7M$91.7M2.0%$38.91-36.23%
6 qtrssince 2020-Q4
Increased
73
SILK
SILKDelisted

SILK ROAD MEDICAL INC

2.2M$88.9M2.0%——
6 qtrssince 2020-Q4
Increased
63
ISEE
ISEEDelisted

IVERIC BIO INC

4.9M$82.3M1.8%——
10 qtrssince 2019-Q4
Increased
48
51.9M$81.7M1.8%——
7 qtrssince 2020-Q3
Increased
72
107.8M$79.7M1.8%——
5 qtrssince 2021-Q1
Increased
52
??
INSULET CORPDelisted
Bond
57.6M$76.2M1.7%——
6 qtrssince 2020-Q4
Unchanged
0
??
NUVASIVE INCDelisted
Bond
80M$76.1M1.7%——
5 qtrssince 2021-Q1
Increased
48
$4.5B
AUM
122
Positions
Q1 2022
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q4$5,059,782,00023.2019471616%
2021-Q1$4,758,345,000-5.95750963184%
2021-Q2$5,629,668,00018.3114717407%
2021-Q3$5,123,921,000-8.98360258545%
2021-Q4$4,767,581,000-6.95443977376%
2022-Q1$4,472,946,000-6.17996841585%
Activity profile
$ moved · Q1'22
New24%Increased29%Decreased23%Exited24%
Composition
Equity vs derivatives
Equity>99%Puts0%Calls<1%
Holding period
Avg 1.1 years
<1Q8%1-4Q38%1-2Y36%2Y+18%

Deerfield Management Company, L.P. manages $4.5B across 122 positions as of Q1 2022. Top holdings: GLAUKOS CORP (8.0%), NUVL (6.0%), VTRS (5.0%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$4B
GLAUKOS CORP8.02%
NUVL6.01%
VTRS5.03%
AHCO4.18%
INVITAE CORP3.80%
NBIX3.47%
AERIE PHARMA3.17%
ENVISTA HOLD2.77%
CAREMAX INC2.72%
NATERA INC2.69%
Other2.60%

Portfolio allocation by GICS sector

Sectors2
Healthcare75.33%
Unknown24.67%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used